FDA Says Effexor XR Ad Overstates Antidepressant’s Second-Line Utility
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth no longer uses the journal ad targeted in warning letter, firm tells The Pink Sheet DAILY.
You may also be interested in...
Lilly’s Cymbalta Wins FDA Approval For Major Depression Maintenance Therapy
The battle with Wyeth’s competing SNRI Effexor XR for new indications continues; Cymbalta could see an indication for fibromyalgia in 2008.
Effexor XR Labeling Update Advises Of Increased Risk Of Fatal Outcomes Versus SSRIs
Wyeth issues “Dear Healthcare Provider” letter advising that venlafaxine overdose may be associated with increased risk of fatal outcomes.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.